DavidHurleyMcKennaJr.MD

Pathology • Minneapolis, MN

Blood Banking & Transfusion Medicine, Transplantation Immunology, Anatomic Pathology, Clinical Pathology

Professor, Lab Medicine & Pathology, University of Minnesota Medical School

Join to view full profile

Dr. McKenna is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McKenna's full profile

Already have an account?

Office
909 Fulton St
Minneapolis, MN 55455

Summary

Dr. David McKenna is a pathologist in Saint Paul, MN. He received his medical degree from Saint Louis University School of Medicine and has been in practice 20 years. He specializes in blood banking & transfusion medicine, transplantation immunology, anatomic pathology, and clinical pathology and is experienced in hematopoietic stem cell transplantation and cellular immunity.

Education & Training

University of MinnesotaFellowship, Transfusion Medicine, 2001 - 2003
University of MinnesotaResidency, Pathology-Anatomic and Clinical, 1997 - 2003
Saint Louis University School of MedicineClass of 1997

Certifications & Licensure

MN State Medical License 2003 - 2025
VT State Medical License 1997 - 1998
American Board of Pathology Anatomic Pathology & Clinical Pathology
American Board of Pathology Blood Banking/Transfusion Medicine

Clinical Trials

Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases Start of enrollment: 2007 May 01
Terminated
Phase 1
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Start of enrollment: 2007 Jul 23
Completed
Phase 1
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Start of enrollment: 2008 Jun 01
Terminated
Phase 1
Stem Cell Therapy in Patients With Severe Heart Failure & Undergoing Left Ventricular Assist Device Placement Start of enrollment: 2011 Nov 10
Completed
Phase 1, Phase 2
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML) Start of enrollment: 2010 Jul 01
Terminated
Phase 2
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies Start of enrollment: 2014 Jan 01
Withdrawn
Phase 1, Phase 2
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation Start of enrollment: 2013 Nov 08
Completed
Phase 1
Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome Start of enrollment: 2013 Jul 01
Completed
Phase 1
Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START) Start of enrollment: 2014 Mar 15
Completed
Phase 2
Treg Cells for AGVHD in Non-myeloablative UCB Transplant Start of enrollment: 2016 Jun 01
Withdrawn
Phase 2
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies Start of enrollment: 2017 Feb 16
Terminated
Phase 2
Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome Start of enrollment: 2019 Nov 26
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Cryopreservation of mesenchymal stem/stromal cells using a DMSO-free solution is comparable to DMSO-containing cryoprotectants: results of an international multicenter...
Theodros Mamo, Cheryl A Cox, Connor Demorest, Magali J Fontaine, Allison Hubel
Cytotherapy. 2024-12-01
2 citations
Local manufacturing processes contribute to variability in human mesenchymal stromal cell expansion while growth media supplements contribute to variability in gene ex...
Beth H Shaz, Richard Schäfer, Magali J Fontaine, Philip J Norris, David H McKenna
Cytotherapy. 2024-06-01
1 citations
Safety and Virologic Impact of Haploidentical NK Cells Plus Interleukin 2 or N-803 in HIV Infection.
Jeffrey S Miller, Joshua Rhein, Zachary B Davis, Sarah Cooley, David McKenna
The Journal of Infectious Diseases. 2024-05-15

Abstracts/Posters

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multip...
David H. McKenna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Uni...
David H. McKenna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Groundbreaking U of M Medical School Muscle Regeneration Research Receives Nearly $1 Million GrantSeptember 3rd, 2019